Sustained release of proteins from a modified vaginal ring device

Ryan J Morrow, A David Woolfson, Louise Donnelly, Rhonda M Curran, Gavin P Andrews, Dietmar Katinger, R Karl Malcolm

    Research output: Contribution to journalArticle

    38 Citations (Scopus)

    Abstract

    A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.
    LanguageEnglish
    Pages3-10
    JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
    Volume77
    DOIs
    Publication statusPublished - 2011

    Fingerprint

    Female Contraceptive Devices
    Equipment and Supplies
    Proteins
    Elastomers
    Silicones
    Tablets
    Gels
    HIV
    Technology
    Peptides
    Antibodies

    Cite this

    Morrow, R. J., Woolfson, A. D., Donnelly, L., Curran, R. M., Andrews, G. P., Katinger, D., & Malcolm, R. K. (2011). Sustained release of proteins from a modified vaginal ring device. European Journal of Pharmaceutics and Biopharmaceutics, 77, 3-10. https://doi.org/10.1016/j.ejpb.2010.10.010
    Morrow, Ryan J ; Woolfson, A David ; Donnelly, Louise ; Curran, Rhonda M ; Andrews, Gavin P ; Katinger, Dietmar ; Malcolm, R Karl. / Sustained release of proteins from a modified vaginal ring device. In: European Journal of Pharmaceutics and Biopharmaceutics. 2011 ; Vol. 77. pp. 3-10.
    @article{ba326f348dee48b29a06495a7fe4e06f,
    title = "Sustained release of proteins from a modified vaginal ring device",
    abstract = "A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.",
    author = "Morrow, {Ryan J} and Woolfson, {A David} and Louise Donnelly and Curran, {Rhonda M} and Andrews, {Gavin P} and Dietmar Katinger and Malcolm, {R Karl}",
    year = "2011",
    doi = "10.1016/j.ejpb.2010.10.010",
    language = "English",
    volume = "77",
    pages = "3--10",
    journal = "European Journal of Pharmaceutics and Biopharmaceutics",
    issn = "0939-6411",
    publisher = "Elsevier",

    }

    Morrow, RJ, Woolfson, AD, Donnelly, L, Curran, RM, Andrews, GP, Katinger, D & Malcolm, RK 2011, 'Sustained release of proteins from a modified vaginal ring device', European Journal of Pharmaceutics and Biopharmaceutics, vol. 77, pp. 3-10. https://doi.org/10.1016/j.ejpb.2010.10.010

    Sustained release of proteins from a modified vaginal ring device. / Morrow, Ryan J; Woolfson, A David; Donnelly, Louise; Curran, Rhonda M; Andrews, Gavin P; Katinger, Dietmar; Malcolm, R Karl.

    In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 77, 2011, p. 3-10.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Sustained release of proteins from a modified vaginal ring device

    AU - Morrow, Ryan J

    AU - Woolfson, A David

    AU - Donnelly, Louise

    AU - Curran, Rhonda M

    AU - Andrews, Gavin P

    AU - Katinger, Dietmar

    AU - Malcolm, R Karl

    PY - 2011

    Y1 - 2011

    N2 - A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.

    AB - A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.

    U2 - 10.1016/j.ejpb.2010.10.010

    DO - 10.1016/j.ejpb.2010.10.010

    M3 - Article

    VL - 77

    SP - 3

    EP - 10

    JO - European Journal of Pharmaceutics and Biopharmaceutics

    T2 - European Journal of Pharmaceutics and Biopharmaceutics

    JF - European Journal of Pharmaceutics and Biopharmaceutics

    SN - 0939-6411

    ER -